1. Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin receptor, a 2002 perspective. Endor Rev 2002; 23: 141–74.
2. Kessler MJ, Reddy MS, Shah RH, Bahl OP. Structures of N-glycosidic carbohydrate units of human choronic gonadotropins. J Biochem 1979; 254: 7901–8.
3. Itskovitz J, Boldes R, Levron J et al. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonists. Fertil Steril 1991; 56 (2): 213–20.
4. Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at midcycle: a reevaluation. J Clin Endocrinol Metab 1983; 57: 792–6.
5. Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal consequences. Trends Endocrinol Metab. 2003; 4: 236–42.
6. McElhinney B, Ardill J, Caldwell C et al. Ovarian hyperstimulation syndrome and assisted reproductive technologies: why some and not others? Hum Reprod 2002; 17 (6): 1548–53.
7. Мартазанова Б.А., Вторушина В.В., Ипен С.М. и др. Содержание ангиогенных факторов и интерлейкина-8 в сыворотке крови и фолликулярной жидкости пациенток с высоким риском развития синдрома гиперстимуляции яичников при замене триггера овуляции. Акушерство и гинекология. 2015; 1: 58–65. / Martazanova B.A., Vtorushina V.V., Ipen S.M. i dr. Soderzhanie angiogennykh faktorov i interleikina-8 v syvorotke krovi i follikuliarnoi zhidkosti patsientok s vysokim riskom razvitiia sindroma giperstimuliatsii iaichnikov pri zamene triggera ovuliatsii. Akusherstvo i ginekologiia. 2015; 1: 58–65. [in Russian]
8. Chen SU, Chou CH, Lin CW et al. Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways. Hum Reprod 2010; 25 (3): 757–67.
9. Castillo JC, Humaidan P, Bernabeu R. Pharmaceutical options for triggering of final oocyte maturation in ART. BioMed Res Int 2014; article ID 580171.
10. Кулаков В.И., Калинина Е.А., Корнеева И.Е. и др. Лечение синдрома гиперстимуляции яичников, как осложнение программы ЭКО и ПЭ. В кн.: Лечение женского и мужского бесплодия. Вспомогательные репродуктивные технологии в лечении женского и мужского бесплодия. Под ред. В.И.Кулакова. М., 2005. / Kulakov V.I., Kalinina E.A., Korneeva I.E. i dr. Lechenie sindroma giperstimuliatsii iaichnikov, kak oslozhnenie programmy EKO i PE. V kn.: Lechenie zhenskogo i muzhskogo besplodiia. Vspomogatel'nye reproduktivnye tekhnologii v lechenii zhenskogo i muzhskogo besplodiia. Pod red. V.I.Kulakova. M., 2005. [in Russian]
11. Mocanu E., Redmond M L, Hennelly B et al. 2007 Odds of ovarian hyperstimulation syndrome (OHSS)-time for reassessment.Human Fertility 10,175-181.
12. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome. Human Reproduction Update 2003;9:77–96.
13. Engmann L, DiLuigi A, Schmidt D et al. The use of gonadotropin releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008; 89 (1): 84–91. DOI: :10.1016/j.fertnstert.2007.02.002
14. Al-Shawaf T, Grudzinskas JG. Prevention and treatment of ovarian hyperstimulation syndrome. Best Pract Res Clin Obstet Gynecol 2003; 17: 249–61.
15. Mathur RS Akande AV, Keay SD et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000; 73: 901–7.
16. Корнеева И.Е., Иванова А.В., Баркалина Н.В. Синдром гиперстимуляции яичников: профилактика, диагностика, лечение (обзор литературы). Проблемы репродукции. 2004; 10 (1): 43–50. / Korneeva I.E., Ivanova A.V., Barkalina N.V. Sindrom giperstimuliatsii iaichnikov: profilaktika, diagnostika, lechenie (obzor literatury). Problemy reproduktsii. 2004; 10 (1): 43–50. [in Russian]
17. Назаренко Т.А. Стимуляция функции яичников. М., 2009. / Nazarenko T.A. Stimuliatsiia funktsii iaichnikov. M., 2009. [in Russian]
18. Diedich K, Diedich C, Santos E. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin- releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Hum Reprod 1994; 9 (5): hh 788–91.
19. Albano C, Smitz J, Camus M et al. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997; 67 (5): 917–22.
20. Gordon K, Williams RF, Danforth DR, Hodgen GD. The combined use of GnRH antagonists with gonadotrophins or pulsatile GnRH in ovulation induction. In: Bouchard P, Caraty A, Coelingh-Bennink HJT, Pavlou SN (eds). GnRH-Analougs, Gonadotrophins and Gonadal Peptides. London: Parthenon Publishing Group, 1993.
21. Gonen Y, Balakier H, Powell W, Casper RF. Use of GnRh agonist to trigger follicular Maturation for in vitro fertilization. J Clin Endocrinol Metab 1990; 71: 918–22.
22. Itskovitz J, Boldes R, Levron J et al. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991; 56: 213–20.
23. Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at mid cycle: a reevaluation. J Clin Endocrinol Metab 1983; 57: 792–6.
24. Zelinski-Wooten MB, Hutchinson JS, Hess DL et al. Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin releasing hormone antagonist-treated monkeys. Hum Reprod 1995; 10: 1658–66.
25. Yding Anderson C, Leonardsen L, Ulloa-Aguirre A et al. FSH-induced resumption of meiosis in mouse oocytes: effect of different isoforms. Mol Hum Reprod 1999; 5: 726–31.
26. Stickland S, Beer WH. Studies on the role of plasminogen activator in ovulation. In vitro response of granulose cells to gonadotropins, cyclic nucleotides and prostaglandins. J Biol Chem 1976; 251: 5694–702.
27. Eppig JJ. FSH stimulates hyaluronic acid synthesis by oocyte-cumuluc cell complexes from mouse preovulatory follicles. Nature 1979; 281: 483–4.
28. Atef A, Francois P, Christian V, Marc-Andre S. The potential role of gap junction communication between cumulus cells and bovine ocytes during in vitro maturation. Mol Reprod Dev 2005; 71 (3): 358–67.
29. Godard NM, Pukazhenthi BS, Wildt DT, Comizzoli P. Paracrine factors from cumulus-enclosed ocytes ensure the successful maturation and fertilization in vitro of denuded oocytes in the cat model. Fertil Steril 2009; 91 (Suppl. 5): 2051–60.
30. Lamb JD, McCulloch C, Jalalian L et al. Follicle stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. Fertil Steril 2011; 95: 1655–60.
31. D’Alessandris C, Canipari R, Di Giacomo M et al. Control of mouse cumulus cell-oocyte complex integrity before and after ovulation: plasminogen activator synthesis and matrix degradation. Endocrinology 2001; 142: 3033–40.
32. Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online 2010; 20: 783–8.
33. Humaidan P, Bredkjaer HE, Bungum L et al. GnRH agonist(buserelin) or HCG for ovulation induction in GnRHnantagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005; 20: 1213–20.
34. Fauser BC, de Jong D, Olivennes F et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002; 87: 709–15.
35. Kolibianakis EM, Schultze-Mosgau A, Schroer A et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005; 20: 2887–92.
36. Galindo A, Bodri D, Jose Guillen J et al. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol 2009; 25: 60–6.
37. Melo M, Busso CE, Bellver J et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessorblind study. Reprod Biomed Online 2009; 19: 486–92.
38. Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod 2006; 21: 1894–900.
39. Casper RF, Yen SS. Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor. Science 1979; 205: 408–10.
40. Sugino N, Kaskida S, Takiguchi S et al. Expression of vascular endothelial growth factor and its receptors in the human corpus luteum during the menstrual cycle and in early pregnancy. J Clin Endocrinol 2000; 85: 3919–24.
41. Wang TH, Horng SG, Chang CL et al. Human chorionic gonadotropin-induced hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 2002; 87: 3300–8.
42. Robinson RS, Nicklin LT, Hammond AJ et al. Fibroblast growth factor 2 is more dynamic than vascular endothelial growth factor A during the follicle-luteal transition in the cow. Biol Reprod 2007; 77: 28–36.
43. Berisha B, Steffl M, Amselgruber W, Schams D. Changes in fibroblast growth factor 2 and its receptors in bovine follicles before and after GnRH application and after ovulation. Reproduction 2006; 131: 319–29.
44. Licht P, Russu V, Wildt L. On the role of human chorionic gonadotropin (hCG) in the embryo-endometrial microenvironment: implications for differentiation and implantation. Semin Reprod Med 2001; 19: 37–47.
45. Rao CV. Multiple novel roles of luteinizing hormone. Fertil Steril 2001; 76: 1097–100.
46. Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 2009; 18: 630–4.
47. Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C. 1500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010; 93: 847–54.
48. Shapiro BS, Daneshmand ST, Garner FC et al. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertil Steril 2008; 90: 231–3.
49. Yamoto M, Minami S, Nakano R. Immunohistochemical localization of inhibin subunits in human corpora lutea during menstrual cycle and pregnancy. J Clin Endocrinol Metab 1991; 73: 470–7.
50. Treetampinich C, O’Connor AE, MacLachlan V et al. Maternal serum inhibin A concentrations in early pregnancy after IVF and embryo transfer reflect the corpus luteum contribution and pregnancy outcome. Hum Reprod 2000; 15: 2028–32.
51. Muttukrishna S, Child TJ, Groome NP, Ledger WL. Source of circulating levels of inhibin A, pro alpha C-containing inhibins and activin A in early pregnancy. Hum Reprod 1997; 12: 1089–93.
52. Nevo O, Eldar-Geva T, Kol S, Itskovitz-Eldor J. Lower levels of inhibin A and pro-alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin. Fertil Steril 2003; 79: 1123–8.
53. Devroey P, Polynoz NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod 2011; 26: 2593–7.
54. Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 2006; 13: 173–8.
55. Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 2009; 18: 630–4.
56. Humaidan P, Polyzos NP, Alsbjerg B et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013; 28 (9): 2511–21.
57. Youssef MA, van der Veen F, Al-Inany HG et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014; 10.

________________________________________________

1. Ascoli M, Fanelli F, Segaloff DL. The lutropin/choriogonadotropin receptor, a 2002 perspective. Endor Rev 2002; 23: 141–74.
2. Kessler MJ, Reddy MS, Shah RH, Bahl OP. Structures of N-glycosidic carbohydrate units of human choronic gonadotropins. J Biochem 1979; 254: 7901–8.
3. Itskovitz J, Boldes R, Levron J et al. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonists. Fertil Steril 1991; 56 (2): 213–20.
4. Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at midcycle: a reevaluation. J Clin Endocrinol Metab 1983; 57: 792–6.
5. Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal consequences. Trends Endocrinol Metab. 2003; 4: 236–42.
6. McElhinney B, Ardill J, Caldwell C et al. Ovarian hyperstimulation syndrome and assisted reproductive technologies: why some and not others? Hum Reprod 2002; 17 (6): 1548–53.
7. Martazanova B.A., Vtorushina V.V., Ipen S.M. i dr. Soderzhanie angiogennykh faktorov i interleikina-8 v syvorotke krovi i follikuliarnoi zhidkosti patsientok s vysokim riskom razvitiia sindroma giperstimuliatsii iaichnikov pri zamene triggera ovuliatsii. Akusherstvo i ginekologiia. 2015; 1: 58–65. [in Russian]
8. Chen SU, Chou CH, Lin CW et al. Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways. Hum Reprod 2010; 25 (3): 757–67.
9. Castillo JC, Humaidan P, Bernabeu R. Pharmaceutical options for triggering of final oocyte maturation in ART. BioMed Res Int 2014; article ID 580171.
10. Kulakov V.I., Kalinina E.A., Korneeva I.E. i dr. Lechenie sindroma giperstimuliatsii iaichnikov, kak oslozhnenie programmy EKO i PE. V kn.: Lechenie zhenskogo i muzhskogo besplodiia. Vspomogatel'nye reproduktivnye tekhnologii v lechenii zhenskogo i muzhskogo besplodiia. Pod red. V.I.Kulakova. M., 2005. [in Russian]
11. Mocanu E., Redmond M L, Hennelly B et al. 2007 Odds of ovarian hyperstimulation syndrome (OHSS)-time for reassessment.Human Fertility 10,175-181.
12. Delvigne A, Rozenberg S. Review of clinical course and treatment of ovarian hyperstimulation syndrome. Human Reproduction Update 2003;9:77–96.
13. Engmann L, DiLuigi A, Schmidt D et al. The use of gonadotropin releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril 2008; 89 (1): 84–91. DOI: :10.1016/j.fertnstert.2007.02.002
14. Al-Shawaf T, Grudzinskas JG. Prevention and treatment of ovarian hyperstimulation syndrome. Best Pract Res Clin Obstet Gynecol 2003; 17: 249–61.
15. Mathur RS Akande AV, Keay SD et al. Distinction between early and late ovarian hyperstimulation syndrome. Fertil Steril 2000; 73: 901–7.
16. Korneeva I.E., Ivanova A.V., Barkalina N.V. Sindrom giperstimuliatsii iaichnikov: profilaktika, diagnostika, lechenie (obzor literatury). Problemy reproduktsii. 2004; 10 (1): 43–50. [in Russian]
17. Nazarenko T.A. Stimuliatsiia funktsii iaichnikov. M., 2009. [in Russian]
18. Diedich K, Diedich C, Santos E. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin- releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Hum Reprod 1994; 9 (5): hh 788–91.
19. Albano C, Smitz J, Camus M et al. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997; 67 (5): 917–22.
20. Gordon K, Williams RF, Danforth DR, Hodgen GD. The combined use of GnRH antagonists with gonadotrophins or pulsatile GnRH in ovulation induction. In: Bouchard P, Caraty A, Coelingh-Bennink HJT, Pavlou SN (eds). GnRH-Analougs, Gonadotrophins and Gonadal Peptides. London: Parthenon Publishing Group, 1993.
21. Gonen Y, Balakier H, Powell W, Casper RF. Use of GnRh agonist to trigger follicular Maturation for in vitro fertilization. J Clin Endocrinol Metab 1990; 71: 918–22.
22. Itskovitz J, Boldes R, Levron J et al. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991; 56: 213–20.
23. Hoff JD, Quigley ME, Yen SS. Hormonal dynamics at mid cycle: a reevaluation. J Clin Endocrinol Metab 1983; 57: 792–6.
24. Zelinski-Wooten MB, Hutchinson JS, Hess DL et al. Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin releasing hormone antagonist-treated monkeys. Hum Reprod 1995; 10: 1658–66.
25. Yding Anderson C, Leonardsen L, Ulloa-Aguirre A et al. FSH-induced resumption of meiosis in mouse oocytes: effect of different isoforms. Mol Hum Reprod 1999; 5: 726–31.
26. Stickland S, Beer WH. Studies on the role of plasminogen activator in ovulation. In vitro response of granulose cells to gonadotropins, cyclic nucleotides and prostaglandins. J Biol Chem 1976; 251: 5694–702.
27. Eppig JJ. FSH stimulates hyaluronic acid synthesis by oocyte-cumuluc cell complexes from mouse preovulatory follicles. Nature 1979; 281: 483–4.
28. Atef A, Francois P, Christian V, Marc-Andre S. The potential role of gap junction communication between cumulus cells and bovine ocytes during in vitro maturation. Mol Reprod Dev 2005; 71 (3): 358–67.
29. Godard NM, Pukazhenthi BS, Wildt DT, Comizzoli P. Paracrine factors from cumulus-enclosed ocytes ensure the successful maturation and fertilization in vitro of denuded oocytes in the cat model. Fertil Steril 2009; 91 (Suppl. 5): 2051–60.
30. Lamb JD, McCulloch C, Jalalian L et al. Follicle stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. Fertil Steril 2011; 95: 1655–60.
31. D’Alessandris C, Canipari R, Di Giacomo M et al. Control of mouse cumulus cell-oocyte complex integrity before and after ovulation: plasminogen activator synthesis and matrix degradation. Endocrinology 2001; 142: 3033–40.
32. Oktay K, Turkcuoglu I, Rodriguez-Wallberg KA. GnRH agonist trigger for women with breast cancer undergoing fertility preservation by aromatase inhibitor/FSH stimulation. Reprod Biomed Online 2010; 20: 783–8.
33. Humaidan P, Bredkjaer HE, Bungum L et al. GnRH agonist(buserelin) or HCG for ovulation induction in GnRHnantagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005; 20: 1213–20.
34. Fauser BC, de Jong D, Olivennes F et al. Endocrine profiles after triggering of final oocyte maturation with GnRH agonist after cotreatment with the GnRH antagonist ganirelix during ovarian hyperstimulation for in vitro fertilization. J Clin Endocrinol Metab 2002; 87: 709–15.
35. Kolibianakis EM, Schultze-Mosgau A, Schroer A et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of HCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 2005; 20: 2887–92.
36. Galindo A, Bodri D, Jose Guillen J et al. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol 2009; 25: 60–6.
37. Melo M, Busso CE, Bellver J et al. GnRH agonist versus recombinant HCG in an oocyte donation programme: a randomized, prospective, controlled, assessorblind study. Reprod Biomed Online 2009; 19: 486–92.
38. Pirard C, Donnez J, Loumaye E. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study. Hum Reprod 2006; 21: 1894–900.
39. Casper RF, Yen SS. Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor. Science 1979; 205: 408–10.
40. Sugino N, Kaskida S, Takiguchi S et al. Expression of vascular endothelial growth factor and its receptors in the human corpus luteum during the menstrual cycle and in early pregnancy. J Clin Endocrinol 2000; 85: 3919–24.
41. Wang TH, Horng SG, Chang CL et al. Human chorionic gonadotropin-induced hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 2002; 87: 3300–8.
42. Robinson RS, Nicklin LT, Hammond AJ et al. Fibroblast growth factor 2 is more dynamic than vascular endothelial growth factor A during the follicle-luteal transition in the cow. Biol Reprod 2007; 77: 28–36.
43. Berisha B, Steffl M, Amselgruber W, Schams D. Changes in fibroblast growth factor 2 and its receptors in bovine follicles before and after GnRH application and after ovulation. Reproduction 2006; 131: 319–29.
44. Licht P, Russu V, Wildt L. On the role of human chorionic gonadotropin (hCG) in the embryo-endometrial microenvironment: implications for differentiation and implantation. Semin Reprod Med 2001; 19: 37–47.
45. Rao CV. Multiple novel roles of luteinizing hormone. Fertil Steril 2001; 76: 1097–100.
46. Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 2009; 18: 630–4.
47. Humaidan P, Ejdrup Bredkjaer H, Westergaard LG, Yding Andersen C. 1500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010; 93: 847–54.
48. Shapiro BS, Daneshmand ST, Garner FC et al. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertil Steril 2008; 90: 231–3.
49. Yamoto M, Minami S, Nakano R. Immunohistochemical localization of inhibin subunits in human corpora lutea during menstrual cycle and pregnancy. J Clin Endocrinol Metab 1991; 73: 470–7.
50. Treetampinich C, O’Connor AE, MacLachlan V et al. Maternal serum inhibin A concentrations in early pregnancy after IVF and embryo transfer reflect the corpus luteum contribution and pregnancy outcome. Hum Reprod 2000; 15: 2028–32.
51. Muttukrishna S, Child TJ, Groome NP, Ledger WL. Source of circulating levels of inhibin A, pro alpha C-containing inhibins and activin A in early pregnancy. Hum Reprod 1997; 12: 1089–93.
52. Nevo O, Eldar-Geva T, Kol S, Itskovitz-Eldor J. Lower levels of inhibin A and pro-alphaC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human chorionic gonadotropin. Fertil Steril 2003; 79: 1123–8.
53. Devroey P, Polynoz NP, Blockeel C. An OHSS-Free Clinic by segmentation of IVF treatment. Hum Reprod 2011; 26: 2593–7.
54. Humaidan P, Bungum L, Bungum M, Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 2006; 13: 173–8.
55. Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 2009; 18: 630–4.
56. Humaidan P, Polyzos NP, Alsbjerg B et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013; 28 (9): 2511–21.
57. Youssef MA, van der Veen F, Al-Inany HG et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014; 10.

С.М.Ипен*1, Н.Г.Мишиева2, Б.А.Мартазанова2, Т.В.Донцова2, С.В.Павлович1,2

1. ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2;
2. ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России. 117997, Россия, Москва, ул. Академика Опарина, д. 4
*dr.snehaeapen@gmail.com

________________________________________________

S.M.Eapen*1, N.G.Mishiyeva2, B.A.Martazanova2, T.V.Dontsova2, S.V.Pavlovich1,2

1. I.M.Sechenov First Moscow State Medical University. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2;
2. V.I.Kulakov Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4
*dr.snehaeapen@gmail.com